1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sana Lifted By Allo-CAR-T Data, Moves Ahead Into Autoimmune Disease

 
• By Andrew McConaghie

Sana claims to has cracked one of allo-CAR-Ts biggest challenges, blocking NK cells from destroying the therapies, and for now, investors are impressed.

Sana

Sana has won over investors with new early data from its off-the-shelf CAR-T candidate, SC291, the results suggesting its ‘hypoimmune modified’ design might overcome some of field’s long-standing obstacles.

Key Takeaways

  • Hopes of a breakthrough in allo-CAR-Ts have been dashed repeatedly, but Sana thinks its Phase I results are significant

The initial results from the Phase I ARDENT trial concern six patients with a variety of different lymphomas. Three out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.